Navigation Links
Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals, Inc. (Amex: PRW), a company "Advancing Drugs Through Glycoscience(R)", today updated the progress of its Phase II clinical trial for first-line treatment of metastatic, unresectable colorectal cancer patients who are unable to tolerate irinotecan and/or oxaliplatin, and its Phase II clinical trial for first-line treatment of biliary cancer patients. Treatment for both indications may represent orphan drug status for DAVANAT(R), the Company's target delivery compound. In addition, the Company plans to submit the manufacturing data requested by the FDA this year for DAVANAT(R) 505 (b)(2) filings as a functional excipient.

Phase II, First Line Treatment, Colorectal Cancer Trial

To date, eight patients have been dosed with DAVANAT(R) in combination with 5-FU, Avastin(R) and leucovorin. Two patients have tumor shrinkage of greater than 30%, a partial response according to Response Evaluation Criteria for Solid Tumors (RECIST). Five patients have stable disease for up to seven months and one had non-drug related progressive disease. Patients experienced no increase in drug-related toxicity and reduced side effects with increased exposure to 5-FU and AVASTIN(R). The Simon two-stage designed study is an open-label, multi-center trial. The primary objectives of the trial are tumor shrinkage and progression-free survival. Six sites are actively recruiting patients. Additional sites are expected to be active shortly. Nine of 25 (36%) end-stage colorectal cancer patients from Phase I/II trials were stabilized from 2 to 8 months.

Phase II, First Line Treatment, Biliary Cancer Trial

To date, seven patients have been dosed with DAVANAT(R) in combination with 5-FU. One patient has tumor shrinkage of greater than 30%, a partial response according to RECIST. Five patients have stable disease for up to five months and one had non-drug related
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
4. NCCN Updates Esophageal and Gastric Cancer Guidelines
5. Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
10. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
11. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
Post Your Comments:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2Investment Analysis of the US Medical Device Sector 2
... 10, 2012 uVera Diagnostics has introduced the CR3 Keyless ... screening specimen cup provides several state-of-the-art features not available ... "This is revolutionary to the drug testing industry," said Rick ... designed for ease of use for both genders. The unique ...
...  - Agreement allows development for potential treatment of ... SHPGY ), the global specialty biopharmaceutical company, ... develop and market Resolor ® (prucalopride) in the ... N.V.  Terms of the agreement have not been disclosed. ...
Cached Medicine Technology:uVera Diagnostics Offers New Drug Screening Product 2Shire Acquires US Rights to Resolor(R) (prucalopride) 2Shire Acquires US Rights to Resolor(R) (prucalopride) 3Shire Acquires US Rights to Resolor(R) (prucalopride) 4
(Date:12/24/2014)... (PRWEB) December 24, 2014 Risperdal lawsuit ... a mass tort litigation currently underway in Pennsylvania’s Philadelphia ... As of December 24, 2014, court documents indicate that ... behalf of individuals who developed gynecomastia (male breast growth) ... from the Court indicates that this represents an increase ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial ... and med-spa with the addition of new Silk Peel ... treatments and services. , “Silk Peel is a procedure ... Ho. “As a result it can address issues like ... discolorations or blemishes.” , Similar to microdermabrasion, Silk ...
(Date:12/24/2014)... December 25, 2014 Today, UWDress.com, the famous ... sleeve wedding gowns, and launched a site-wide wedding gown promotion. ... sleeve wedding gowns in a more unexpected way, the collection ... are popular in the global market, and they are available ... UWDress.com are offered at discounted prices, up to 75% off; ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 BambooIndustry.com a ... for many years. Today, the company announces its ... a special offer on these new products. , Bamboo ... renewable bamboo. The multiple layer bamboo panel board features ... both strong and emissions free. The bamboo panel consists ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2
... experts say, but safety concerns linger, , WEDNESDAY, Jan. ... oral, rather than injected -- may soon be available to ... online Jan. 20 in the New England Journal of ... cladribine -- reduce relapse rates in people with relapsing-remitting multiple ...
... Implications of Federal Medicare Cuts Require Careful Scrutiny and Consideration ... AUSTIN, Texas , Jan. 20 The ... Graves , today expressed concern about the growing cumulative pressure ... and protect Texas, most vulnerable nursing home residents. ...
... ... significantly higher risk of relapse attacks in patients with multiple sclerosis (MS) who develop the ... San Francisco. , ... 20, 2010 -- Low vitamin D blood levels are associated with a significantly higher ...
... ... market of medical silicone components. , ... Chicago, IL (PRWEB) January 20, 2010 -- Chicago-based medical silicone component manufacturer ... to market faster. , , , , ,FMI’s Rapid Development Program (RDP) is ...
... to Develop and Oversee Marketing and Strategic Partnership Initiatives ... WASHINGTON , Jan. 20 The Patient Advocate ... arbitration services to tens of thousands of patients every year ... of financial obstacles or insurance denials -- announced today the ...
... , ... to Haiti , Craig Juntunen , founder of Chances for Children, ... assist in a fresh renewal of the devastated nation of Haiti , ... Hole residents Lynn and Foster Friess augmented by a subsequent ...
Cached Medicine News:Health News:First Oral Medications For MS Show Promise 2Health News:First Oral Medications For MS Show Promise 3Health News:Texas Health Care Association: Meeting Texas Seniors' Ongoing Care Needs Threatened by Looming State, Federal Funding Threats 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 2Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 3Health News:Low Vitamin D Levels are Associated With Greater Risk of Relapse in Childhood-Onset Multiple Sclerosis 4Health News:FMI Introduces Rapid Development Program for Medical Silicone Components 2Health News:Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships 2Health News:Patient Advocate Foundation Welcomes Former NASCAR Team Executive as New Executive Vice President of National Partnerships 3Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 2Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 3Health News:Chances for Children Launches 'Haiti Renewal Fund' With $2 Million From Foster Friess 4
... the first intra-operative fluorescent imaging system ... the location of the coronary arteries ... coronary artery bypass procedures. ,The patented ... to view, record, replay, print, and ...
... When myocardial infarction is ... TROPT sensitive rapid assay allows ... marker troponin T from a ... qualitative result is available within ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... The White Sun light source offers the industry ... Kelvin color temperature at a lower price. A ... White Sun to be used with Olympus, Storz, ... light output LED and re-settable bulb timer. The ...
Medicine Products: